Grants for Public housing authorities - Health

This funding opportunity provides support for research projects that utilize health information technology to improve healthcare access, quality, and outcomes for underserved populations in the U.S. experiencing health disparities.

The grant titled "BRAIN Initiative: Engineering and optimization of molecular technologies for functional dissection of neural circuits" aims to support the development and enhancement of molecular tools that can specifically target brain cells, enabling the observation and control of neural circuits in experimental animals.

This funding opportunity supports researchers conducting early phase clinical trials on natural products, such as botanicals and dietary supplements, to evaluate their effects on health and inform future studies.

This funding opportunity provides financial support for researchers to develop innovative screening methods and therapies for newborn conditions, aiming to improve early detection and management of potentially serious health issues in infants.

The purpose of the NINDS Alzheimers Disease and Alzheimers Disease-Related Dementias (AD/ADRD) Advanced Postdoctoral Career Transition Award to Promote Diversity (K99/R00) program is to support of a cohort of new and talented, independent investigators from diverse backgrounds conducting AD/ADRD research. The program is designed to facilitate a timely transition of promising postdoctoral researchers from diverse backgrounds (e.g., see NIHs Interest in Diversity) from their mentored, postdoctoral research positions to independent, tenure-track or equivalent faculty positions. The program will provide independent NIH research support during this transition in order to help awardees establish independent research programs in the AD/ADRD field. This FOA is designed specifically for applicants proposing research that does not involve leading an independent clinical trial, a clinical trial feasibility study, or an ancillary study to a clinical trial. Applicants to this FOA are permitted to propose research experience in a clinical trial led by a mentor or co-mentor.

This(NOFO) aims to innovate, implement, and evaluate approaches to One Health laboratory diagnostic network optimization and specimen transport in Liberia. This multi-component NOFO is designed to address the inter-dependence of a comprehensive, resource-mapped, accredited national and sub-national laboratory network, the physical transportation architecture required to transfer network commodities (namely human, animal, and environmental specimens) point-to-point, and the optimization of digital communication, information, and supply chain systems necessary to sustain the network itself.

This Notice of Funding Opportunity (NOFO) invites applications from institutions/organizations that propose to establish a Research Resource Center (RRC) for the NIDDK Nutrition Obesity Research Centers (NORC) Program. The NORC Program consists of eleven Centers across the nation that support and enhance the national research effort in nutrition and obesity through cutting-edge basic, clinical, translational, and health disparities research in nutrition science and obesity. In collaboration with the existing NORC program, the RRC will (1) provide administrative support for the entire NORC Program, (2) establish and curate a NORC Program website and centralized repository of research resources , (3) implement a multipronged approach to support and grow the early-to-midcareer research workforce, including individuals from diverse backgrounds, with a goal of maximizing national outreach and impact, (4) administer and manage a NORC Opportunity Program to address gaps and promote collaboration, and (5) manage a Pilot and Feasibility Program.This NOFO requires a Plan for Enhancing Diverse Perspectives (PEDP), which will be assessed as part of the scientific and technical peer review evaluation. Applications that fail to include a PEDP will be considered incomplete and will be withdrawn.

Funding Opportunity Description Developing medical countermeasures to protect civilians against intentional and accidental toxic chemical exposure that can lead to mass casualties is a major goal of the biodefense program at NIH. More specifically, this goal is executed by the Chemical Countermeasures Research Program (CCRP) at NIAID in partnership with several other ICs across the NIH (NIH Strategic Plan and Research Agenda for Medical Countermeasures Against Chemical Threats). NIAMS has been a critical and active partner in this trans-NIH effort since the CCRP’s inception in 2006. In order to broaden its research base and raise the awareness of the scientific community at large about the urgent need for effective countermeasures against chemical threats, the CCRP is encouraging its IC partners to issue IC-specific FOAs to further engage their respective research disciplines that are not currently engaged in the medical countermeasure research field. This initiative is a response to that request. The intent of the initiative is to encourage the NIAMS skin research community to contribute to the basic understanding of injuries caused by those toxic chemicals identified by the U.S. Department of Homeland Security as high consequence public health threats and to explore the local and systemic mechanisms of chemical wound development, healing, and long-term consequences. It is envisaged that such initiative will benefit both the national civilian defense program as well as the basic skin wound healing research at large. This initiative will emphasize understanding commonalities in the fundamental mechanisms of skin injuries caused by vesicants such as sulfur mustard, Lewisite, nitrogen mustard, phosgene oxime, and arsenicals, which may be different from thermal burn. The investigators are also encouraged to collaborate with researchers in tissues other than skin that are affected by the vesicants (e.g., eyes and lung) to find commonalities of injury mechanisms shared with skin. It is hoped that the fundamental knowledge gained would ultimately lead to the discovery and characterization of potential shared therapeutic targets (e.g., in signal transduction pathways and inflammation process) and the development of broad-spectrum medical countermeasures. This FOA is intended for investigators who are not currently supported under the CCRP’s CounterACT program but whose research interests are relevant to skin chemical injuries and to skin wound healing in general. It is assumed that the proposed project will represent a new direction for the applicant, which requires the applicant’s research lab to acquire new skills (e.g., handling toxic chemicals), gather new resources (e.g., establishing collaborative or contractual relationships with facilities certified to utilize restricted/controlled chemicals) and generate new preliminary data. Therefore, this FOA uses a planning mechanism (R34) to support such investigators to commence the preparatory steps toward this new line of study. This means that the applicants do not need to present preliminary data supporting the proposed study in concept, nor publication records and specific skills and proficiency in experimental execution in the chemical medical countermeasures field. However, the PD/PI should demonstrate prior experience in wound healing research and general knowledge relating to skin injury and healing. It is expected that a successful outcome of a proposed project is that the investigator has added within the laboratory (if needed) personnel with the skills and expertise to conduct studies in this area, established a working relationship with facilities certified for toxic chemicals (if needed), and gathered sufficient preliminary data to support a more comprehensive research project suitable under the other more translationally-focused CCRP FOAs.

This funding opportunity supports research projects that explore innovative combinations of radiation therapy and other treatments to improve cancer care, inviting applications from a diverse range of organizations, including universities, nonprofits, and for-profit entities.

This funding opportunity supports small-scale research projects that aim to improve the use of genomic information in clinical care, particularly for diverse and historically underrepresented populations.

The "Identify and Evaluate Potential Risk Factors for Amyotrophic Lateral Sclerosis (ALS)" grant is a $2.5 million funding opportunity from the CDC and ATSDR, aimed at supporting research to better understand potential risk factors for ALS, with a focus on environmental and occupational exposures, military service, traumatic brain injury, neuroinflammation, contact sports, and infectious agents, especially in underrepresented populations.

This funding opportunity provides financial support to local governments and nonprofits in U.S. territories and freely associated states for infrastructure maintenance and resilience projects that enhance community development and disaster preparedness.

This Funding Opportunity Announcement (FOA) invites applications to develop and implement Phase Ib to III clinical trials of promising pharmacological and non-pharmacological interventions that may prevent, delay, or treat the symptoms of Alzheimer's disease (AD) and other age-related dementias using the Alzheimer's disease Clinical Trials Consortium (ACTC) trial coordination and management infrastructure.Research Objectives Utilizing the ACTC, the goal of this FOA is to invite research grant applications that provide clinical testing (Phases Ib-III) of promising pharmacological and/or non-pharmacological interventions for cognitive and neuropsychiatric symptoms in individuals with AD or other aging-related dementias across the spectrum from pre-symptomatic to more severe stages of disease. Working with the ACTC is a cooperative venture between the applicant, the NIA, and the ACTC network. NIA and the ACTC leadership will provide guidance to potential applicants. Potential applicants are strongly encouraged to contact NIA Scientific/Research Contacts (see Agency Contacts, Section VII) and the ACTC study team in order to discuss the feasibility of conducting the proposed trial through the ACTC infrastructure before considering an application. The ACTC infrastructure is welcoming of the following: Academic and industry applicants Pharmacological and non-pharmacological interventions Applications are encouraged that propose the following: Testing candidate therapeutic compounds against novel therapeutic targets Testing repurposed drugs derived from data-driven approaches, including candidates coming from NIA's translational bioinformatics FOA (PAR-17-032) Logistical guidance: Potential applicants undergo initial vetting of proposed study by the ACTC protocol evaluation committee and final review by the steering committee. Applicants should contact the ACTC study team at least 5 months prior to their desired NIA submission cycle. Contact details and more information may be found at actcinfo.org. Applications should anticipate using a centralized IRB. Applicants should be aware of the data and resource sharing requirements. The use of common contract language is strongly encouraged. Note, the ACTC infrastructure is not appropriate for: Single site clinical trials Routine Phase Ia first-in-human Clinical trials funded from this FOA will be implemented through the ACTC. The clinical trials approved for funding will develop their final protocols in conjunction with the ACTC. All ACTC sites will have the option to request participation and will be selected based on their capabilities specific to the individual protocols. Investigators are strongly encouraged to collect blood and other biosamples for future genomic and other 'omic' analyses aimed at interrogating treatment responsiveness and examining predictors of decline and progression. See Section VIII. Other Information for award authorities and regulations.

This funding opportunity is designed to support higher education institutions, nonprofit organizations, and other eligible entities in establishing a coordination center to advance research on how our bodies sense and respond to internal signals, with a focus on improving mental health and overall wellness.

This funding opportunity supports innovative research exploring how social isolation and loneliness contribute to suicide risk among older adults, particularly focusing on underrepresented communities and various social factors.

NIEHS invites applications for cooperative agreements to support the development of model programs for the training and education of workers engaged in activities related to hazardous materials and waste generation, removal, containment, transportation and emergency response within the Department of Energy (DOE) nuclear weapons complex. The aim of this funding opportunity is to prevent work-related harm through safety and health training. The training programs consist of information and practical exercises with the objective of raising the knowledge of workers in protecting themselves and the community from being exposed to hazardous materials encountered during hazardous waste operations; facility decommissioning and decontamination; hazardous materials transportation; environmental restoration of contaminated facilities; or chemical emergency response. Currently, tens of thousands of DOE employees are required to complete safety and health training. The goal of this training is to help reduce the risk of workers being exposed during work activities to hazardous materials and hazardous waste products. The NIEHS/DOE Nuclear Worker Training Program enhances training capabilities at these sites.

The National Center for Advancing Translational Sciences (NCATS) intends to publish aNotice of Funding Opportunity (NOFO) to solicit applications for research to advance the diagnosis, management, and treatment of rare diseases. Each Rare Diseases Clinical Research Consortium (RDCRC) will promote highly collaborative, multi-site, patient-centric, translational, and clinical research. It is strongly encouraged that the RDCRC study outcome measures include those that address unmet clinical trial readiness needs that will move the field of research forward from its current state. This Notice is being provided to allow potential applicants sufficient time to develop meaningful collaborations and responsive projects. The NOFO is expected to be published in winter 2024, with an expected application due date in summer 2024. This NOFO will utilize the U54 activity code, which supports specialized centers through multi-project cooperative agreement awards to support research activities with substantial involvement from NIH program staff. Details of the planned NOFO are provided below.

This funding opportunity supports organizations in planning and hosting an annual conference focused on advancing the development of treatments for substance use disorders, bringing together researchers, clinicians, and policymakers to foster collaboration and innovation in this critical public health area.

This funding opportunity supports research projects that aim to reduce health disparities related to HIV and substance use among underserved racial and ethnic populations in the U.S.

The purpose of this concept is to facilitate the formation and maintenance of multidisciplinary research teams ready to employ epidemiological and/or etiological datasets and analyses to answer substance use prevention research questions and apply findings to intervention development or implementation. Projects supported through this concept will combine hands-on meeting formats, including both sandpit and hackathon approaches, with activities to sustain new research teams and networks, creating a foundational structure for research programs that have impact across disciplines.